New drugs could act through modulation of the skin microbiota and/or stimulation of the innate immune response via AMPs such as S100a8/a9 and certain cytokines such as IL‐1β, thereby being potentially beneficial in conditions such as alopecia areata and other cutaneous diseases. Here, IGKV1D-22 is linked to alopecia areata.